1. Home
  2. TKLF vs CURX Comparison

TKLF vs CURX Comparison

Compare TKLF & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TKLF

Yoshitsu Co. Ltd

N/A

Current Price

$1.63

Market Cap

8.3M

ML Signal

N/A

CURX

Curanex Pharmaceuticals Inc

N/A

Current Price

$5.03

Market Cap

9.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKLF
CURX
Founded
2006
2018
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
9.4M
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
TKLF
CURX
Price
$1.63
$5.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.5K
★ 23.1K
Earning Date
12-19-2025
09-09-2025
Dividend Yield
★ 10.97%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.82
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$0.18
52 Week High
$3.92
$6.80

Technical Indicators

Market Signals
Indicator
TKLF
CURX
Relative Strength Index (RSI) 39.82 67.84
Support Level N/A $3.91
Resistance Level $2.43 $6.00
Average True Range (ATR) 0.11 0.48
MACD 0.00 -0.10
Stochastic Oscillator 14.12 82.67

Price Performance

Historical Comparison
TKLF
CURX

About TKLF Yoshitsu Co. Ltd

Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.

Share on Social Networks: